Cyclic sulfones as novel P3-caps for hepatitis C virus NS3/4A (HCV NS3/4A) protease inhibitors: Synthesis and evaluation of inhibitors with improved potency and pharmacokinetic profiles

Journal of Medicinal Chemistry

Volumn 53, Issue 8, 2010, Pages 3075-3085

  Velázquez, Francisco ^a   Sannigrahi, Mousumi ^a   Bennett, Frank ^a   Lovey, Raymond G ^a   Arasappan, Ashok ^a   Bogen, Stéphane ^a   Nair, Latha ^a   Venkatraman, Srikanth ^a   Blackman, Melissa ^a   Hendrata, Siska ^a   Huang, Yuhua ^a   Huelgas, Regina ^a   Pinto, Patrick ^a   Cheng, Kuo Chi ^a   Tong, Xiao ^a   McPhail, Andrew T ^a   Njoroge, F George ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BETA METHYLCYCLOHEXYLGLYCINE; BOCEPREVIR; CYCLOHEXYLMETHYLUREA; CYCLOPROPANE DERIVATIVE; GLYCINE DERIVATIVE; N [1 [2 (CYCLOPROPYLAMINO) 1,2 DIOXOETHYL]BUTYL] 6,6 DIMETHYL 3 [2 (1 METHYLCYCLOHEXYL) 2 [[[[1 (TETRAHYDRO 1,1DIOXIDO 2 THIENYL)CYCLOHEXYL]AMINO]CARBONYL]AMINO]ACETYL] 3 AZABICYCLO[3.1.0]HEXANE 2 CARBOXAMIDE; N [1 [2 (CYCLOPROPYLAMINO) 1,2 DIOXOETHYL]PENTYL] 6,6 DIMETHYL 3 [2 (1 METHYLCYCLOHEXYL) 2 [[[[1 (TETRAHYDRO 1,1 DIOXIDO 2 THIENYL)CYCLOHEXYL]AMINO]CARBONYL]AMINO]ACETYL] 3 AZABICYCLO[3.1.0]HEXANE 2 CARBOXAMIDE; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4A; PROTEINASE INHIBITOR; SULFONE DERIVATIVE; TERT BUTYLUREA; UNCLASSIFIED DRUG; UREA DERIVATIVE; VIRUS PROTEIN;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG SYNTHESIS; HEPATITIS C; HEPATITIS C VIRUS; MOLECULAR MODEL; MONKEY; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ANIMALS; CRYSTALLOGRAPHY, X-RAY; HAPLORHINI; HEPACIVIRUS; MODELS, MOLECULAR; OLIGOPEPTIDES; RATS; SERINE PROTEINASE INHIBITORS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONES;

EID: 77951143463     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm9016027     Document Type: Article

References (30)

1. World Health Organization (WHO). Hepatitis C. Fact Sheet No. 164. http://www.who.int/mediacentre/factsheets/fs164/en/ (revised October 2000).
2. Wasley, A.; Alter, M. J. Epidemiology of hepatitis C: geographic differences and temporal trends Semin. Liver Dis. 2000, 20, 1-16
3. Brown, R. S., Jr.; Gaglio, P. J. Scope of worldwide hepatitis C problem Liver Transpl. 2003, 9, S10-S13
4. McHutchison, J. G.; Gordon, S. C.; Schiff, E. R.; Shiffman, M. L.; Lee, W. M.; Rustgi, V. K.; Goodman, Z. D.; Ling, M.-H.; Cort, S.; Albrecht, J K. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C N. Engl. J. Med. 1998, 339, 1485-1492
5. Fried, M. W.; Shiffman, M. L.; Reddy, K. R.; Smith, C.; Marinos, G.; Gonales, F. L., Jr.; Häussinger, D.; Diago, M.; Carosi, G.; Dhumeaux, D.; Craxi, A.; Lin, A.; Hoffman, J.; Yu, J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N. Engl. J. Med. 2002, 347, 975-982
6. Choo, Q. L.; Kuo, G.; Weiner, A. J.; Overby, L. R.; Bradley, D. W.; Houghton, M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome Science 1989, 244, 359-362
7. Lindenbach, B. D.; Rice, C. M. Unraveling hepatitis C virus replication from genome to function Nature 2005, 436, 933-938
8. Bartenschlager, R.; Ahlborn-Laake, L.; Mous, J.; Jacobsen, H. Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions J. Virol. 1993, 67, 3835-3844
9. Venkatraman, S.; Bogen, S. L.; Arasappan, A.; Bennett, F.; Chen, K.; Jao, E.; Liu, Y.-T.; Lovey, R.; Hendrata, S.; Huang, Y.; Pan, W.; Parekh, T.; Pinto, P.; Popov, V.; Pike, R.; Ruan, S.; Santhanam, B.; Vibulbhan, B.; Wu, W.; Yang, W.; Kong, J.; Liang, X.; Wong, J.; Liu, R.; Butkiewicz, N.; Chase, R.; Hart, A.; Agrawal, S.; Ingravallo, P.; Pichardo, J.; Kong, R.; Baroudy, B.; Malcolm, B.; Guo, Z.; Prongay, A.; Madision; Broske, L.; Cui, X.; Cheng, K.-C.; Hsieh, T. Y.; Brisson, J.-M.; Prelusky, D.; Korfmacher, W.; White, R.; Boganowich-Knipp, S.; Pavlovsky, A.; Prudence, B.; Saksena, A. K.; Ganguly, A.; Piwinski, J.; Girijavallabhan, V.; Njoroge, F. G. Discovery of (1 R,5 S)- N -[3-amino-1-(cyclobutylmethyl)-2-3-dioxopropyl]-3-[2(S)-[[[(1,1-dimethylethyl) -amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0] hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable, hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infection J. Med. Chem. 2006, 49, 6074-6086
10. Yip, Y.; Victor, F.; Lamar, J.; Johnson, R.; Wang, Q. M.; Glass, J. I.; Yumibe, N.; Wakulchik, M.; Munroe, J.; Chen, S.-H. P4 and P1′ optimization of bicycloproline P2 bearing tetrapeptidyl α-ketoamides as HCV protease inhibitors Bioorg. Med. Chem. Lett. 2004, 14, 5007-5011 (Pubitemid 39165612)
11. Chen, S.-H.; Lamar, J.; Yip, Y.; Victor, F.; Johnson, R. B.; Wang, Q. M.; Glass, J. I.; Heinz, B.; Colacino, J.; Guo, D.; Tebbe, M.; Munroe, J. E. P1 and P1′ optimization of [3,4]-bicycloproline P2 incorporated tetrapeptidyl α-ketoamide based HCV protease inhibitors Lett. Drug Des. Discovery 2005, 2, 118-123
12. Perni, R. B.; Almquist, S. J.; Byrn, R. A.; Chandorkar, G.; Chaturvedi, P. R.; Courtney, L. F.; Decker, C. J.; Dinehart, K.; Gates, C. A.; Harbeson, S. L.; Heiser, A.; Kalkeri, G.; Kolaczkowski, E.; Lin, K.; Luong, Y.-P.; Rao, B. G.; Taylor, W. P.; Thomson, J. A.; Tung, R. D.; Wei, Y.; Kwong, A. D.; Lin, C. Preclinical profile of VX-950, a potent, selective, and orally, bioavailable inhibitor of hepatitis C virus NS3-4A serine protease Antimicrob. Agents Chemother. 2006, 50, 899-909
13. Lamarre, D.; Anderson, P. C.; Bailey, M.; Beaulieu, P.; Bolger, G.; Bonneau, P.; Bös, M.; Cameron, D. R.; Cartier, M.; Cordingley, M. G.; Faucher, A.-M.; Goudreau, N.; Kawai, S. H.; Kukolj, G.; Lagacé, L.; LaPlante, S. R.; Narjes, H.; Poupart, M.-A.; Rancourt, J.; Sentjens, R. E.; George, T, S.; Simoneau, B.; Steinmann, G.; Thibeault, D.; Tsantrizos, Y. S.; Weldon, S. M.; Yong, C.-L.; Llinàs-Brunet, M. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus Nature 2003, 186-189 (Pubitemid 37442587)
14. Llinas-Brunet, M.; Bailey, M. D.; Bolger, G.; Brochu, C.; Faucher, A.-M.; Ferland, J. M.; Garneau, M.; Ghiro, E.; Gorys, V.; Grand-Maitre, C.; Halmos, T.; Lapeyre-Paquette, N.; Liard, F.; Poirier, M.; Rheaume, M.; Tsantrizos, Y. S.; Lamarre, D. Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061 J. Med. Chem. 2004, 47, 1605-1608
15. For ITMS-191: Seiwert, S. D.; Andrews, S. W.; Jiang, Y.; Serebryany, V.; Tan, H.; Kossen, K.; Rajagopalan, P. T. R.; Misialek, S.; Stevens, S. K.; Stoycheva, A.; Hong, J.; Lim, S. R.; Qin, X.; Rieger, R.; Condroski, K. R.; Zhang, H.; Do, M. G.; Lemieux, C.; Hingorani, G. P.; Hartley, D. P.; Josey, J. A.; Pan, L.; Beigelman, L.; Blatt., L. M. Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227) Antimicrob. Agents Chemother. 2008, 52, 4432-4441
16. For MK-7009: Liverton, N. J.; Carroll, S. S.; DiMuzio, J.; Fandozzi, C.; Graham, D. J.; Hazuda, D.; Holloway, M. K.; Ludmerer, S. W.; McCauley, J. A.; McIntyre, C. J.; Olsen, D. B.; Rudd, M. T.; Stahlhut, M.; Vacca, J. P. MK-7009: A Potent and Selective Inhibitor of Hepatitis C Virus NS3/4A Protease Antimicrob. Agents Chemother. 2010, 54, 305-311
17. Bogen, S. L.; Arasappan, A.; Bennett, F.; Chen, K.; Jao, E.; Liu, Y.-T.; Lovey, R. G.; Venkatraman, S.; Pan, W.; Parekh, T.; Pike, R. E.; Ruan, S.; Liu, R.; Baroudy, B.; Agrawal, S.; Chase, R.; Ingravallo, P.; Pichardo, J.; Prongay, A.; Brisson, J.-M.; Hsieh, T. Y.; Cheng, K.-C.; Kemp, S. J.; Levy, O. E.; Lim-Wilby, M.; Tamura, S. Y.; Saksena, A. K.; Girijavallabhan, V.; Njoroge, F. G. Discovery of SCH 446211 (SCH 6): a new ketoamide inhibitor of the HCV NS3 serine protease and HCV subgenomic RNA replication J. Med. Chem. 2006, 49, 2750-2757
18. Zhang, R.; Beyer, B. M.; Durkin, J.; Ingram, R.; Njoroge, F. G.; Windsor, W. T.; Malcolm, B. A. A continuous spectrophotometric assay for the hepatitis C virus serine protease Anal. Biochem. 1999, 270, 268-275
19. Lohmann, V.; Korner, F.; Koch, J.-O.; Herian, U.; Theilmann, L.; Bartenschlager, R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line Science 1999, 285, 110-113
20. Bogen, S.; Weidong, P.; Ruan, S.; Nair, L. G.; Arasappan, A.; Bennett, F.; Chen, K. X.; Jao, E.; Venkatraman, S.; Vibulbhan, B.; Liu, R.; Cheng, K. C.; Guo, Z.; Tong, X.; Saksena, A. K.; Girijavallabhan, V.; Njoroge, F. G. Toward the back-up of boceprevir (SCH 503034): discovery of new extended P4-capped ketoamide inhibitors of hepatitis C virus NS3 serine protease with improved potency and pharmacokinetic profiles J. Med. Chem. 2009, 52, 3679-3688
21. Venkatraman, S.; Blackman, M.; Wu, W.; Nair, L.; Arasappan, A.; Padilla, A.; Bogen, S.; Bennett, F.; Chen, K.; Pichardo, J.; Tong, X.; Prongay, A.; Cheng, K.-C; Girijavallabhan, V.; Njoroge, F. G. Discovery of novel P3 sulfonamide-capped inhibitors of HCV NS3 protease. Inhibitors with improved cellular potencies Bioorg. Med. Chem. 2009, 17, 4486-4495
22. Bennett, F; Huang, Y.; Hendrata, S.; Lovey, R.; Bogen, S. L.; Pan, W.; Guo, Z.; Prongay, A.; Chen, K. X.; Arasappan, A.; Venkatraman, S.; Velazquez, F.; Nair, L.; Sannigrahi, M.; Tong, X.; Pichardo, J.; Cheng, K.-C.; Girijavallabhan, V. M.; Saksena, A. K.; Njoroge, F. G. The introduction of P4 substituted 1-methylcyclohexyl groups into boceprevir: a change in direction in the search for a second generation HCV NS3 protease inhibitor. Bioorg. Med. Chem. Lett. 2010, DOI: 10.1016/j.bmcl.2010.02.063.
23. Unless otherwise indicated, the following parameters were used for rat PK evaluations: rats were orally administered at a dose of 10 mg/kg in 0.4% methylcellulose in water. Blood samples were withdrawn periodically and pooled. AUC was calculated over 0-6 h.
24. Velázquez, F.; Arasappan, A.; Chen, K.; Sannigrahi, M.; Venkatraman, S.; McPhail, A. T.; Chan, T.-M.; Shih, N.-Y.; Njoroge, F. G. Stereoselective synthesis of β-substituted β-amino sulfones and sulfonamides via addition of sulfonyl anions to chiral N -sulfinyl imines Org. Lett. 2006, 8, 789-792
25. Liu, G.; Cogan, D. A.; Owens, T. D.; Tang, T. P.; Ellman, J. A. Synthesis of enantiomerically pure N-tert -butanesulfinyl imines (tert -butanesulfinimines) by the direct condensation of tert -butanesulfinamide with aldehydes and ketones J. Org. Chem. 1999, 64, 1278-1284
26. Crystal structure of compound 19 has been deposited at the Cambridge Crystallographic Data Centre and allocated the deposition number CCDC 763018.
27. On the basis of our previous experience in the development of 1, we decided to use enantiomerically pure P1-groups in all target compounds presented herein to avoid problems associated with handling diastereomeric mixtures.
28. To perform a thorough SAR investigation, selected five- and six-membered analogues having the S -configuration in the cyclic sulfone moiety were prepared for potency and PK comparison. The data collected always favored the analogues having R -configuration in the cyclic sulfone moiety.
29. Mei, H; Korfmacher, W; Morrison, R. Rapid in vivo oral screening in rats: reliability, acceptance criteria, and filtering efficiency AAPS J. 2006, 8 (3) E493-E500
30. Arasappan, A.; Venkatraman, S.; Padilla, A. I.; Wu, W.; Meng, T.; Jin, Y.; Wong, J.; Prongay, A.; Girijavallabhan, V.; Njoroge, F. G. Practical and efficient method for amino acid derivatives containing β-quaternary center: application toward synthesis of hepatitis C virus NS3 serine protease inhibitors Tetrahedron Lett. 2007, 48, 6343-6347